Display options
Cite
Rutkowski P, Kozak K, Mackiewicz J, et al. The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. Contemp Oncol (Pozn). 2015;19(4):280-3doi: 10.5114/wo.2015.54082.
Rutkowski, P., Kozak, K., Mackiewicz, J., Krzemieniecki, K., Nawrocki, S., Wasilewska-Teśluk, E., Kwinta, �. �., Wysocki, P., Koseła-Paterczyk, H., & Świtaj, T. (2015). The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. Contemporary oncology (Poznan, Poland), 19(4), 280-3. https://doi.org/10.5114/wo.2015.54082
Rutkowski, Piotr, et al. "The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial." Contemporary oncology (Poznan, Poland) vol. 19,4 (2015): 280-3. doi: https://doi.org/10.5114/wo.2015.54082
Rutkowski P, Kozak K, Mackiewicz J, Krzemieniecki K, Nawrocki S, Wasilewska-Teśluk E, Kwinta Ł, Wysocki P, Koseła-Paterczyk H, Świtaj T. The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. Contemp Oncol (Pozn). 2015;19(4):280-3. doi: 10.5114/wo.2015.54082. Epub 2015 Sep 28. PMID: 26557775; PMCID: PMC4631301.
Copy Download .nbib Format: NLM
Share it on

Contemp Oncol (Pozn). 2015;19(4):280-3. doi: 10.5114/wo.2015.54082. Epub 2015 Sep 28.

The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial.

Contemporary oncology (Poznan, Poland)

Piotr Rutkowski, Katarzyna Kozak, Jacek Mackiewicz, Krzysztof Krzemieniecki, Sergiusz Nawrocki, Ewa Wasilewska-Teśluk, Łukasz Kwinta, Piotr Wysocki, Hanna Koseła-Paterczyk, Tomasz Świtaj

Affiliations

  1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
  2. Chair of Medical Biotechnology, University of Medical Sciences, Poznan, Poland Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland Medical Oncology Department, Malgorzata Medical Centre, ?rem, Poland Medpolonia sp. z o.o., Poznan, Poland.
  3. Department of Clinical Oncology, Krakow University Hospital, Krakow, Poland.
  4. Division of Radiotherapy and Oncology, Department of Clinical Oncology, Silesian Medical University, Katowice, Poland.
  5. Department of Oncology, University of Warmia and Mazury, Olsztyn, Poland.
  6. Department of Chemotherapy, Greater Poland Cancer Centre, Poznan, Poland.
  7. Department of Clinical Oncology, West Cancer Centre, Szczecin, Poland.

PMID: 26557775 PMCID: PMC4631301 DOI: 10.5114/wo.2015.54082

Abstract

AIM OF THE STUDY: The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Polish oncological centres.

MATERIAL AND METHODS: Patients with untreated or previously treated Stage IIIC/IV BRAFV600 mutation-positive melanoma were treated with oral vemurafenib in an initial dose of 960 mg twice daily. Assessments for safety and efficacy were made every 28 days. For the survival analysis the Kaplan-Meier estimator was used with the log-rank tests for bivariate comparisons.

RESULTS: In total, 75 Polish patients were enrolled in the safety study across four centres. At data cut-off, 28 patients died (37%), mainly (26) due to disease progression; 33 (44%) patients continued vemurafenib after disease progression. The objective response rate was 46%, including two patients with a complete response and 29 with a partial response. Median progression-free survival was 7.4 months. The one-year overall survival rate was 61.9% (median overall survival was not reached). Seventy-three (97.3%) patients reported adverse events (AEs), and grade 3-5 toxicity was reported in 49.4% (37) patients. The most common AEs were: skin lesions (including rash and photosensitivity), arthralgia, and fatigue.

CONCLUSIONS: The overall safety profile and response rate of vemurafenib were comparable to those reported in previous studies of this drug. Our study confirmed the value of well-established prognostic features for overall survival, such as initial LDH (lactate dehydrogenase) level and AJCC staging.

Keywords: BRAF inhibition; melanoma; metastatic; vemurafenib

References

  1. N Engl J Med. 2015 Jan 1;372(1):30-9 - PubMed
  2. Lancet Oncol. 2014 Aug;15(9):954-65 - PubMed
  3. Eur J Cancer. 2014 Feb;50(3):611-21 - PubMed
  4. Contemp Oncol (Pozn). 2012;16(6):532-45 - PubMed
  5. Cancer. 2014 Oct 15;120(20):3142-53 - PubMed
  6. N Engl J Med. 2012 Feb 23;366(8):707-14 - PubMed
  7. Lancet Oncol. 2014 Apr;15(4):436-44 - PubMed
  8. N Engl J Med. 2014 Nov 13;371(20):1877-88 - PubMed
  9. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  10. Lancet Oncol. 2014 Mar;15(3):323-32 - PubMed
  11. Cancer J. 2014 Jan-Feb;20(1):18-24 - PubMed
  12. J Clin Oncol. 2009 Dec 20;27(36):6199-206 - PubMed
  13. N Engl J Med. 2014 Nov 13;371(20):1867-76 - PubMed
  14. Expert Rev Anticancer Ther. 2013 May;13(5):513-22 - PubMed

Publication Types